Rational parameters for antibiotic therapy in patients with cystic fibrosis
- 1 July 1987
- journal article
- research article
- Published by Springer Nature in Infection
- Vol. 15 (4), 300-307
- https://doi.org/10.1007/bf01644142
Abstract
Data from the literature and the authors' experiences were used to review aspects of antibiotic therapy of patients with cystic fibrosis; attention was paid toin vitro antimicrobial susceptibility tests and assessment of therapy directed against mucoidPseudomonas aeruginosa. The heterogeneity ofP. aeruginosa within single sputa with respect to antibiotic susceptibility is stressed. Quantitative viable counts of bacteria based on an analysis of homogenised sputum is recommended. The mode ofin vivo growth of mucoidP. aeruginosa is discussed to explain the survival of hypersusceptibleP. aeruginosa in vivo, and the clinical benefit observed in the absence of a significant reduction of the pathogen. The value of ceftazidime in the treatment of exacerbations due toHaemophilus influenzae is emphasised. The social benefits from oral administration of ciprofloxacin also emphasises that the patient's quality of life must also be considered. In einer Übersicht werden Daten aus der Literatur und eigene Erfahrungen in der Antibiotikatherapie bei Patienten mit zystischer Fibrose dargestellt. DieIn vitro-Testung und klinische Beurteilung der Therapie von Infektionen durch mukoide Stämme vonPseudomonas aeruginosa finden besondere Beachtung.P. aeruginosa-Isolate aus einer einzigen Sputumprobe weisen im Hinblick auf ihre Antibiotikaempfindlichkeit eine bemerkenswerte Heterogenität auf. Keimzahlenbestimmungen sollten an homogenisierten Sputumproben vorgenommen werden. DasIn vivo-Wachstumsverhalten mukoiderP. aeruginosa-Stämme gibt Aufschluß über die Beobachtung, daß hochempfindliche Stämme vonP. aeruginosa in vivo überleben. Auf das Phänomen der klinischen Besserung ohne signifikante Erregerreduktion wird eingegangen. Hervorgehoben wird der Wert von Ceftazidim in der Therapie akuter Exazerbationen durchHaemophilus influenzae. Der soziale Gewinn einer oralen Therapie mit Ciprofloxacin weist auf die Bedeutung der Lebensqualität für den Patienten hin.This publication has 42 references indexed in Scilit:
- Polyagglutinating and non-typable strains of Pseudomonas aeruginosa in cystic fibrosisJournal of Medical Microbiology, 1986
- Chromosomal Loci Associated with Antibiotic Hypersensitivity in Pulmonary Isolates of Pseudomonas aeruginosaMicrobiology, 1984
- Heterogeneity and Reduction in Pulmonary Clearance of Mucoid Pseudomonas aeruginosaClinical Infectious Diseases, 1983
- FREQUENT ANTIBIOTIC THERAPY IMPROVES SURVIVAL OF CYSTIC FIBROSIS PATIENTS WITH CHRONIC PSEUDOMONAS AERUGINOSA INFECTIONActa Paediatrica, 1983
- MICROBIOLOGY OF LUNG INFECTIONS IN CYSTIC FIBROSIS PATIENTSActa Paediatrica, 1982
- Role of exotoxin A and proteases of Pseudomonas aeruginosa in respiratory tract infectionsCanadian Journal of Microbiology, 1982
- Isolation of Alginate-producing Mutants of Pseudomonas fluorescens, Pseudomonas putida and Pseudomonas mendocinaMicrobiology, 1981
- Multiple Isolates of Pseudomonas aeruginosa with Differing Antimicrobial Susceptibility Patterns from Patients with Cystic FibrosisThe Journal of Infectious Diseases, 1979
- A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosisThe Journal of Pediatrics, 1979
- IMMUNE COMPLEXES IN THE SPUTUM OF PATIENTS WITH CYSTIC FIBROSIS SUFFERING FROM CHRONIC PSEUDOMONAS AERUGINOSA LUNG INFECTIONActa Pathologica Microbiologica Scandinavica Section C Immunology, 1978